Printer Friendly

Sun Pharma Gets USFDA Approval for Generic Depakote (R) Delayed Release Tablets.

MUMBAI, July 30 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for generic Depakote (R), divalproex sodium delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches.

These generic versions of divalproex sodium delayed release 125 mg, 250 mg and 500 mg (valproic acid activity) tablets are bio-equivalent to Depakote (R) delayed release tablets distributed by Abbott Laboratories.

These strengths of Depakote (R) delayed release tablets have annual sales of approximately USD 750 million in the US.

These products will reach market shortly.

Depakote (R) is a registered trademark of Abbott Laboratories.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopaedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at

We would be happy to host one-on-one, group and telephone meetings for updates on the Company. If you wish to setup such a meeting, feel free to get in touch with us. In-person meetings can be at our office or elsewhere depending on mutual convenience. Our contact details:

 Uday Baldota
 Tel : +91-22-6645-5645, Ext 605
 Tel Direct: +91-22-6645-5605
 Mobile : +91-98670-10529
 E mail:

 Mira Desai
 Tel: +91-22-6645-5645, Ext 606
 Tel Direct: +91-22-6645-5606
 Mobile: +91-98219-23797
 E mail:

Uday Baldota, Tel: +91-22-6645-5645, Ext 605, Tel Direct: +91-22-6645-5605, Mobile : +91-98670-10529, E mail: Mira Desai, Tel: +91-22-6645-5645, Ext 606, Tel Direct: +91-22-6645-5606, Mobile: +91-98219-23797, E mail:
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Jul 30, 2008
Previous Article:Banco Santander Chile Announces Second Quarter 2008 Earnings.
Next Article:Cytochroma and Mitsubishi Tanabe Form Partnership for Chronic Kidney Disease Therapies in U.S. and Asia.

Related Articles
Sun Pharma Gets USFDA Approval for Generic Fosamax (R) Tablets.
Sun Pharma Continues Strong Performance.
Sun Pharma Receives USFDA Approvals for 4 Generic Products.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters